FNYS
VRDN icon

First New York Securities’s Viridian Therapeutics VRDN Stock Holding History

First New York Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20
Closed -$9.86K – 480
2015
Q2 		$9.86K Buy
+20
New +$8.1K ﹤0.01% 324

Other funds holding VRDN

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

First New York Securities's VRDN Position: Q3 2015 in Review

First New York Securities sold out of Viridian Therapeutics (VRDN) in Q3 2015, closing a stake of 20 shares — an estimated $9.86K sold.

First New York Securities first reported a position in VRDN in Q2 2015 and held it in 1 quarter. The position peaked at $9.86K in Q2 2015. 10 funds tracked by Wall St. Rank hold VRDN as of Q3 2015.

  • First New York Securities reported no remaining Viridian Therapeutics position as of Q3 2015 after selling out during the quarter.
  • First New York Securities sold 20 Viridian Therapeutics shares in Q3 2015, an estimated $9.86K.
  • First New York Securities first reported a position in Viridian Therapeutics in Q2 2015 and held it in 1 quarter.
  • First New York Securities's Viridian Therapeutics position peaked at $9.86K in Q2 2015.
  • 10 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2015.

Based on First New York Securities's 13F filing for Q3 2015, filed 27 Oct 2015.